Key facts
- Mursla Bio’s last known valuation is $53.2M (Apr 2025).
- It has raised $10.2M; the latest was Later Stage VC ($2.2M) in Apr 2025.
- Notable investors include London & Partners., TA Ventures, Government of UK, Grow London.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Mursla Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Mursla Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mursla Bio
Developer of a non-invasive diagnostic platform designed for the early detection of cancer. The company's platform applies extracellular vesicle science and omics analysis, incorporating organ-specific vesicle isolation from biofluids for precise targeting, an artificial intelligence-enabled workflow for disease biomarker identification, and a scalable assay system using optimal markers for clinical use, enabling healthcare providers to improve outcomes for at-risk patients.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 17
- Website
- mursla.com/
- Ownership
- Privately Held (backing)
Mursla Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mursla Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mursla Bio in its N-PORT filings yet. We sweep new filings monthly.